The poor experience of the HTA Review was predictable and predicted. While, in many ways, it might be too late to correct, there are valuable lessons that can guide advocacy over the years ahead. The primary lesson is prioritising caution over misplaced and frankly naive enthusiasm for controlled processes run by the all-powerful single-payer.
The process looked like a teddy bear, but a closer look has revealed a hidden risk
March 11, 2024 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Government moves on general co-pay as safety net gets further out of reach
July 29, 2025 - - Latest News -
'For these families, genomics is not a luxury—it’s the only viable path'
July 29, 2025 - - Latest News -
Pharmac identifies the wider societal benefit of treatments for chronic conditions
July 28, 2025 - - Latest News -
Australian cell therapy company appoints experienced executive as CEO
July 28, 2025 - - Australian Biotech -
Alterity Therapeutics reports positive topline data from Phase 2 trial of ATH434
July 28, 2025 - - Australian Biotech -
Radiopharm Theranostics receives IND approval to initiate Phase 1 study
July 28, 2025 - - Australian Biotech -
Clarity successfully completes $203 million institutional placement
July 28, 2025 - - Australian Biotech